Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis

Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis

header-info

Momelotinib proved superior to danazol for key outcomes in a phase 3 trial of patients with symptomatic and anemic myelofibrosis.